Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma
- PMID: 27144432
- PMCID: PMC5095079
- DOI: 10.18632/oncotarget.9104
Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma
Abstract
As the conventional staging systems have poor prognosis prediction ability for patients with perihilar cholangiocarcinoma (pCCA), we established and validated an effective prognostic nomogram for pCCA patients based on their personal and tumor characteristics. A total of 235 patients who received curative intent resections at the Eastern Hepatobiliary Surgery Hospital from 2000 to 2009 were recruited as the primary training cohort. Age, preoperative CA19-9 levels, portal vein involvement, hepatic artery invasion, lymph node metastases, and surgical treatment outcomes (R0 or R1/2) were independent prognostic factors for pCCA patients in the primary cohort as suggested by the multivariate analyses and these were included in the established nomogram. The calibration curve showed good agreement between overall survival probability of pCCA patients for the nomogram predictions and the actual observations and the concordance index (C-index) was 0.68 (95% CI, 0.61-0.71). The C-index values and time-dependent ROC tests suggested that the nomogram is superior to the conventional staging systems including the Bismuth-Corlette, Gazzaniga, Memorial Sloan Kettering Cancer Center (MSKCC), American Joint Committee on Cancer (AJCC) TNM 7th edition, and Mayo Clinic. The nomogram also performed better than the traditional staging system in the internal cohort with 93 pCCA patients from the same institution and an external validation cohort including 84 pCCA patients from another institution in predicting the overall survival of the pCCA patients as suggested by the C-index values and the time-dependent ROC tests. In summary, the proposed nomogram has superior predictive accuracy of prognosis for resectable pCCA patients.
Keywords: nomogram; overall survival; perihilar cholangiocarcinoma.
Conflict of interest statement
The authors have declared no conflicts of interest.
Figures



Similar articles
-
Development and external validation of a nomogram for predicting the effect of tumor size on survival of patients with perihilar cholangiocarcinoma.BMC Cancer. 2020 Oct 30;20(1):1044. doi: 10.1186/s12885-020-07501-0. BMC Cancer. 2020. PMID: 33126868 Free PMC article.
-
A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma.J Gastrointest Surg. 2016 Oct;20(10):1716-24. doi: 10.1007/s11605-016-3203-2. Epub 2016 Jul 13. J Gastrointest Surg. 2016. PMID: 27412318 Free PMC article.
-
Survival analysis of patients with stage T2a and T2b perihilar cholangiocarcinoma treated with radical resection.BMC Cancer. 2020 Sep 3;20(1):849. doi: 10.1186/s12885-020-07357-4. BMC Cancer. 2020. PMID: 32883228 Free PMC article.
-
The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis.Medicine (Baltimore). 2018 Aug;97(34):e11999. doi: 10.1097/MD.0000000000011999. Medicine (Baltimore). 2018. PMID: 30142840 Free PMC article.
-
[Perihilar cholangiocarcinoma (Klatskin tumor)].Chirurg. 2014 Feb;85(2):155-65; quiz 166-7. doi: 10.1007/s00104-012-2390-y. Chirurg. 2014. PMID: 24464335 Review. German.
Cited by
-
Outcome and validation of a new clinically based staging system for predicting survival of perihilar cholangiocarcinoma patients.JGH Open. 2017 Oct 6;1(2):56-61. doi: 10.1002/jgh3.12009. eCollection 2017 Oct. JGH Open. 2017. PMID: 30483535 Free PMC article.
-
Predictive model for the intraoperative unresectability of hilar cholangiocarcinoma: Reducing futile surgical exploration.PLoS One. 2022 Apr 13;17(4):e0258522. doi: 10.1371/journal.pone.0258522. eCollection 2022. PLoS One. 2022. PMID: 35417458 Free PMC article.
-
A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma.Cancer Med. 2018 Mar;7(3):646-654. doi: 10.1002/cam4.1341. Epub 2018 Feb 23. Cancer Med. 2018. PMID: 29473340 Free PMC article.
-
Surgery for cholangiocarcinoma.Liver Int. 2019 May;39 Suppl 1(Suppl Suppl 1):143-155. doi: 10.1111/liv.14089. Liver Int. 2019. PMID: 30843343 Free PMC article. Review.
-
Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients.Int J Clin Oncol. 2021 Apr;26(4):717-727. doi: 10.1007/s10147-020-01846-z. Epub 2021 Jan 2. Int J Clin Oncol. 2021. PMID: 33387086
References
-
- Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H, British Society of G Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657–1669. - PubMed
-
- Williams TM, Majithia L, Wang SJ, Thomas CR., Jr Defining the role of adjuvant therapy: cholangiocarcinoma and gall bladder cancer. Semin Radiat Oncol. 2014;24:94–104. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials